TAK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	1.85M
Average Volume	1.57M
Market Cap	41.89B
EPS	$0 ( 2024-05-09 )
Next earnings date	( $0 ) 2024-06-26
Last Dividend	$0.301 ( 2024-03-27 )
Next Dividend	$0 ( N/A )
P/E	46.03
ATR14	$0.00900 (0.07%)

Volume Correlation

Long: 0.55 (weak)

Short: 0.60 (weak)

Signal:(57.853) Neutral

Takeda Pharmaceutical Correlation

10 Most Positive Correlations
CATO	0.93
TLK	0.929
NSTB	0.921
GLL	0.91
TLYS	0.908
BF-A	0.907
AMWL	0.904
CMP	0.901
DZZ	0.9
DGZ	0.897

10 Most Negative Correlations
RTX	-0.935
UCIB	-0.932
FTAI	-0.932
EDR	-0.929
HMY	-0.925
GCC	-0.924
SCCO	-0.924
GATO	-0.922
GLD	-0.921
GLDM	-0.921

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Takeda Pharmaceutical Correlation - Currency/Commodity

0.41
( neutral )

-0.14
( neutral )

0.00
( neutral )

-0.51
( weak negative )

-0.74
( moderate negative )

Takeda Pharmaceutical Financials

Annual	2024
Revenue:	$4 263.76B
Gross Profit:	$2 184.97B (51.25 %)
EPS:	$92.09

FY	2024
Revenue:	$4 263.76B
Gross Profit:	$2 184.97B (51.25 %)
EPS:	$92.09

FY	2023
Revenue:	$4 027.48B
Gross Profit:	$2 783.41B (69.11 %)
EPS:	$204.29

FY	2022
Revenue:	$3 569.01B
Gross Profit:	$2 462.16B (68.99 %)
EPS:	$147.14

Financial Reports:

No articles found.

Takeda Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.270 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.261 (N/A)	$0 (N/A)	$0.301 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Takeda Pharmaceutical Dividend Information - Dividend Knight

Dividend Sustainability Score: 6.86 - average (95.53%) | Divividend Growth Potential Score: 4.99 - Stable (0.16%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.470	2008-09-25
Last Dividend	$0.301	2024-03-27
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	29	--
Total Paid Out	$12.44	--
Avg. Dividend % Per Year	2.42%	--
Score	3.53	--
Div. Sustainability Score	6.86
Div.Growth Potential Score	4.99
Div. Directional Score	5.93	--

Next Divdend (Est)
(2024-07-15)

$0.299 Estimate 12.21 %

Dividend Stability

0.49 Below Average

Dividend Score

3.53

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2008	$0.470	3.54%
2009	$1.000	6.24%
2010	$0.533	4.02%
2011	$1.135	7.11%
2012	$1.110	7.35%
2013	$0.894	5.57%
2014	$0.822	4.87%
2015	$0.730	4.62%
2016	$0.829	4.27%
2017	$0.798	4.71%
2018	$0.802	3.34%
2019	$0.828	4.92%
2020	$0.850	4.27%
2021	$0.804	4.47%
2022	$0.270	1.96%
2023	$0.261	1.66%
2024	$0.301	2.10%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend King	2023-06-30	Quarterly	2	5.23%	8.53
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50
ARR	Dividend Royal	2024-05-14	Monthly	15	11.08%	8.50
ACV	Dividend Royal	2024-06-13	Monthly	10	10.19%	8.50
ACP	Dividend Royal	2024-05-22	Monthly	14	11.88%	8.50
AVK	Dividend Royal	2024-05-14	Monthly	22	9.54%	8.31
AFG	Dividend Royal	2024-04-12	Bi-Monthly	39	9.39%	8.06
JPT	Dividend King	2023-11-02	Monthly	8	4.19%	8.05
VCIF	Dividend Royal	2023-08-18	Monthly	6	8.05%	8.02
EDI	Dividend Royal	2023-12-07	Monthly	13	8.85%	7.94

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0338	1.500	9.32	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00954	1.200	9.68	10.00	[0 - 0.3]
returnOnEquityTTM	0.0206	1.500	-0.882	-1.324	[0.1 - 1]
payoutRatioTTM	1.993	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.106	0.800	9.47	7.58	[1 - 3]
quickRatioTTM	0.500	0.800	-1.768	-1.414	[0.8 - 2.5]
cashRatioTTM	0.198	1.500	-0.0116	-0.0174	[0.2 - 2]
debtRatioTTM	0.321	-1.500	4.66	-6.99	[0 - 0.6]
interestCoverageTTM	1.022	1.000	-0.733	-0.733	[3 - 30]
operatingCashFlowPerShareTTM	452.81	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	146.32	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.666	-1.500	7.34	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.622	1.000	2.97	2.97	[0.2 - 0.8]
operatingProfitMarginTTM	0.0527	1.000	-0.946	-0.946	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.147	1.000	-0.297	-0.297	[0.2 - 2]
assetTurnoverTTM	0.282	0.800	-1.452	-1.162	[0.5 - 2]
Total Score				6.86

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	22.86	1.000	7.79	0	[1 - 100]
returnOnEquityTTM	0.0206	2.50	-0.567	-1.324	[0.1 - 1.5]
freeCashFlowPerShareTTM	146.32	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0268	1.500	9.33	0	[0 - 0.4]
operatingCashFlowPerShareTTM	452.81	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.993	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	0.0212	1.500	-3.19	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.167	1.000	8.34	0	[0.1 - 0.5]
Total Score				4.99

Takeda Pharmaceutical Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.